Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.

[1]  A. Drilon,et al.  Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. , 2022, Journal of Clinical Oncology.

[2]  E. Sokol,et al.  Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer , 2022, JCO precision oncology.

[3]  E. Sokol,et al.  Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population , 2021, npj Precision Oncology.

[4]  L. Bazhenova,et al.  TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting , 2021, Targeted Oncology.

[5]  D. Hong,et al.  Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer , 2021, Clinical Cancer Research.

[6]  Wei Zhang,et al.  A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors , 2020, Therapeutic advances in medical oncology.

[7]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[8]  B. Taylor,et al.  TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations , 2019, Clinical Cancer Research.

[9]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[10]  A. Chou,et al.  NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases , 2019, Modern Pathology.

[11]  K. Bencardino,et al.  Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Drilon,et al.  TRK inhibitors in TRK fusion-positive cancers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Zehir,et al.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.

[14]  M. Ladanyi,et al.  High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden , 2019, Clinical Cancer Research.

[15]  Liliana Villafania,et al.  Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. , 2019, Cancer research.

[16]  Reprint of: Mahalanobis, P.C. (1936) "On the Generalised Distance in Statistics." , 2018, Sankhya A.

[17]  James X. Sun,et al.  Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. , 2018, Journal of gastrointestinal oncology.

[18]  V. Miller,et al.  Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings , 2018 .

[19]  A. Iafrate,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. , 2017, JCO precision oncology.

[20]  James X. Sun,et al.  ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer , 2017, Journal of the National Cancer Institute.

[21]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[22]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[23]  A. Isacchi,et al.  Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. , 2016, Journal of medicinal chemistry.

[24]  R. Doebele,et al.  TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.

[25]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[26]  M. Nikiforova,et al.  ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancer , 2014, Cancer.

[27]  J. Bishop,et al.  Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. , 2013, Human pathology.

[28]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[29]  Elizabeth A Stuart,et al.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[30]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[31]  S. O’Rahilly,et al.  A de novo mutation affecting human TrkB associated with severe obesity and developmental delay , 2004, Nature Neuroscience.

[32]  E. H. Goulding,et al.  Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor , 2003, Nature Neuroscience.

[33]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[34]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.

[35]  P. Sorensen,et al.  Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. , 2000, The American journal of surgical pathology.

[36]  M. Pierotti,et al.  The Gly571arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor , 2000, Journal of cellular physiology.

[37]  H. Tonoki,et al.  Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis , 1996, Nature Genetics.

[38]  M. Barbacid,et al.  Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death , 1993, Cell.

[39]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.